¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"specific inflammation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • proliferative inflammation
    Áõ½Ä¿°Áõ
  • pseudomembranous inflammation
    °ÅÁþ¸·¿°Áõ, À§¸·¿°Áõ
  • purulent inflammation
    °í¸§¿°Áõ, È­³ó¿°Áõ
  • reactive inflammation
    ¹ÝÀÀ¿°Áõ
  • rheumatic inflammation
    ·ù¸¶Æ¼½º¿°Áõ
  • suppurative inflammation
    °í¸§¿°Áõ, È­³ó¿°Áõ
  • sclerosing inflammation
    °æÈ­¿°Áõ
  • serofibrinous inflammation
    Àå¾×¼¶À¯¼Ò¿°Áõ, Àå¾×ÇǺ기¿°Áõ
  • serous inflammation
    Àå¾×¼º¿°Áõ
  • ulcerative inflammation
    ±Ë¾ç¿°Áõ
  • age-specific death rate
    ¿¬·Éº°»ç¸Á·ü
  • age-specific fertility rate
    ¿¬·Éº°»ý½Ä·ü
  • age-specific rate
    ¿¬·Éº°ºñÀ²
  • cause-specific rate
    ¿øÀκ°ºñÀ²
  • donor-specific phage
    Á¦°øÀÚÆ¯ÀÌÆÄÁö, °ø¿©ÀÚÆ¯ÀÌÆÄÁö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • proliferative inflammation
    Áõ½Ä¿°Áõ
  • pseudomembranous inflammation
    °ÅÁþ¸·¿°Áõ
  • purulent inflammation
    (¢¡suppurative inflammation) °í¸§¿°Áõ, È­³ó¿°Áõ
  • reactive inflammation
    ¹ÝÀÀ¿°Áõ
  • rheumatic inflammation
    ·ù¸¶Æ¼½º¿°Áõ
  • sclerosing inflammation
    °æÈ­¿°Áõ
  • serofibrinous inflammation
    Àå¾×¼¶À¯¿°Áõ
  • serous inflammation
    Àå¾×¿°Áõ
  • suppurative inflammation
    °í¸§¿°Áõ, È­³ó¿°Áõ
  • ulcerative inflammation
    ±Ë¾ç¿°Áõ
  • age-specific rate
    ¿¬·Éº°Æ¯¼öÀ²
  • age-specific death rate
    ¿¬·Éº°Æ¯¼ö»ç¸Á·ü
  • age-specific fertility rate
    ¿¬·Éº°Ãâ»êÀ²
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • granulocyte-specific antigens
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group specific C carbohydrate
    ±ºÆ¯ÀÌ C´Ù´çü.
  • group-specific
    ±ºÆ¯ÀÌÀÇ
  • group-specific C carbohydrate
    ±ºÆ¯ÀÌ C ź¼öÈ­¹°
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • group-specific antigen
    ±º-ƯÀÌÇ׿ø
  • idiotype specific regulatory cell
    °³º°Æ¯ÀÌÇü Á¶Àý¼¼Æ÷
  • immunity, specific
    ƯÀ̸鿪
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • pneumococcal [specific] polysaccharide
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • polysaccharide, pneumococcal [specific]
    Æó·Å±¸±Õ(ƯÀÌ)´Ù´ç·ù
  • prostate specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø
  • prostate-specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø(îñí¡àÍ÷åì¶ù÷ê«)
  • prostatic specific antigen
    Àü¸³¼± ƯÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • inflammation,leukocytic exudation
    ¹éÇ÷±¸¼º »ïÃâ¹°(ÛÜúìϹàõ ¡­)
  • inflammation,lysosomal constituents
    ¸®¼Ò¼Ø(¿ëÇØ¼Òü)((éÁú°á³ô÷) à÷ÝÂ)
  • inflammation,necrotizing
    ±«»ç¼º(ÎÕÞÝàõ)
  • inflammation,plasma proteases
    Ç÷Àå ÇÁ·ÎÅ×¾ÆÁ¦(úìíì ¡­)
  • inflammation,vascular flow and caliber
    Ç÷°üÇ÷·ù(úìηúì×µ)¿Í±¸°æ(Ï¢ÌÓ)
  • inflammation,vascular permeability
    Åõ°ú¼º(úìη ÷âΦàõ)
  • interstitial inflammation
    °£Áú¼º ¿°(Áõ).(¡­ æú(ñø))
  • interstitital inflammation
    °£Áú¼º ¿°Áõ(¡­ æúñø)
  • mechanical inflammation =MI
    ±â°èÀû ¿°Áõ(¡­æúñø).
  • membranous inflammation
    ¸·¼º¿°Áõ(¡­àõæúñø)
  • metastatic inflammation
    ÀüÀ̼º ¿°Áõ(¡­æúñø).
  • necrotic inflammation =necrotizing i.
    ±«»ç¼º ¿°(ÎÕÞÝàõæú).(º´¸®) ±«»ç¼º ¿°Áõ.
  • necrotic inflammation =necrotizing i.
    ±«»ç¼º ¿°(ÎÕÞÝàõæú). ±«»ç¼º ¿°Áõ( ¡­ æúñø)
  • necrotizing inflammation
    ±«»ç¼º ¿°Áõ(¡­æúñø)
  • obliterative inflammation
    Æó»ö¼º ¿°Áõ.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • specific gravity
    ºñÁß(Ýïñì)
  • specific growth rate
    ºñ¼ºÀåÀ²(Ýïà÷íþëÒ)
  • specific heat
    ºñ¿­(Ýïæð)
  • specific immune suppression
    ƯÀÌ ¸é¿ª¾ï¾Ð(÷åì¶Øóæ¹åääâ)
  • specific immunity
    ƯÀ̸鿪(÷åì¶Øóæ¹)
  • specific interaction theory
    ƯÀÌ »óÈ£ÀÛ¿ëÀÌ·Ð(÷åì¶ßÓû»íÂéÄ×âÖå)
  • specific ionization
    ºñ(Ýï) ÀÌ¿ÂÈ­(ûù)
  • specific radioactivity
    ºñ¹æ»ç´É(ÝïÛ¯ÞÒÒö)
  • specific rate constant
    ƯÀÌ ¼Óµµ»ó¼ö(÷åì¶áÜÓøßÈâ¦)
  • specific reaction rate
    ƯÀÌ ¹ÝÀÀ¼Óµµ(÷åì¶ÚãëëáÜÓø)
  • specific refractive index increment
    ƯÀÌ ±¼ÀýÁö¼ö Áõ°¡(÷åì¶ÏÝï¹ò¦â¦ñòÊ¥)
  • specific retention volume
    ºñ Àú·ù ¿ëÀû(ÝïîÍ×µé»îÝ)
  • specific rotation
    ºñ¼±±¤µµ(ÝïàÁÎÃÓø)
  • specific rotatory power
    ºñ¼±±¤·Â(ÝïàÁÎÃÕô)
  • specific substrate concentration
    ƯÀÌ ±âÁú³óµµ(÷åì¶ÐñòõÒØÓø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NAI net acid input; no accidental injury; no acute inflammation; nonadherence index
NIP nipple; no infection present; no inflammation present
NSI negative self-image; no signs of infection/inflammation; non-syncytium-inducing
SI International System of Units [Fr. le Systeme International d'Unites]; sacroiliac; saline infusion; ...
HBsAg/adr hepatitis B surface antigen manifesting group-specific determinant a and subtype-specific determinan...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BsAbs Bi-specific antibodies
BALP Bone specific alkaline phosphatase
BAP Bone specific alkaline phosphatase
CSS Cause specific survival
CNSLD Chronic non-specific lung disease
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • simple inflammation
    ´Ü¼ø ¿°Áõ
  • sterile inflammation
    ¹«±Õ¼º ¿°Áõ
  • subacute inflammation
    ¾Æ±Þ¼º ¿°Áõ
  • ulcerative inflammation
    ±Ë¾ç¼º ¿°Áõ
  • cell cycle-non specific
    ¼¼Æ÷ Áֱ⠺ñƯÀ̼º Á¦Á¦
  • donor-specific phage
    °ø¿©±Õ ƯÀÌ ÆÄÁö
  • nociceptive specific
    Ä§ÇØ ¼ö¿ë¼º ƯÀ̼º, À¯ÇØ ¼ö¿ë¼º ƯÀ̼º
  • nociceptive-specific cell
    Ä§ÇØ ¼ö¿ë-ƯÀ̼º ¼¼Æ÷, À¯ÇØ ¼ö¿ë-ƯÀ̼º ¼¼Æ÷
  • nociceptive-specific neuron
    Ä§ÇØ ¼ö¿ë-ƯÀ̼º ´º¿ì·±, À¯ÇØ ¼ö¿ë-ƯÀ̼º ´º¿ì·±
  • non-specific arousal system
    ºñƯÀ̼º °¢¼º°è
  • non-specific response
    ºñƯÀ̼º ¹ÝÀÀ
  • specific
    ƯÀÌÇÑ, Á¾ÀÇ, Á¾Á·ÀÇ, ƯÀÌÀÇ, ƯÀ̼ºÀÇ, ƯÀÌÀûÀÎ
    1. ÇÑ Á¾·ùÀÇ ¹Ì»ý¹°¿¡ ÀÇÇØ¼­ »ê»ýµÇ´Â. 2. Ư¼ö¼ºÀÇ. Àû¿ë, È¿°ú µîÀÌ Æ¯Á¤ÇÑ ±¸Á¶, ±â´É µî¿¡ ÇÑÁ¤µÈ. 3. ƯȿÀÇ ¾î¶² ƯÁ¤ Áúȯ¿¡ ´ëÇØ¼­ Ưº°È÷ À¯È¿ÇÑ ÀǾàǰ. 4. ¸é¿ªÇп¡ À־ ´ëÀÀÇÏ´Â Ç×ü¿¡ ´ëÇÑ Ç׿øÀÇ Æ¯º°ÇÑ Ä£È­¼º¿¡ °üÇÑ.
  • specific activity
    ƯÀÌ È°¼º, ƯÀÌ È°¼ºµµ, ºñȰ¼º, ºñȰ¼ºµµ
  • specific alopecia
    Ư¼ö Å»¸ðÁõ
  • specific congenital heart defects
    °³º° º´¼Ò
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
sclerosing inflammation Inflammation leading to extensive formation of fibrous and scar tissue.
(05 Mar 2000)
pseudomembranous inflammation A form of exudative inflammation that involves mucous and serous membranes; relatively large quantities of fibrin in the exudate result in a rather tenacious membrane-like covering that is fairly adherent to the underlying acutely inflamed tissue; the pseudomembrane usually contains (in addition to the dense network of fibrin) varying quantities of plasma protein, degenerated and necrotic elements from the affected tissue, polymorphonuclear leukocytes, bacteria, etc.
(05 Mar 2000)
purulent inflammation An acute exudative inflammation in which the accumulation of polymorphonuclear leukocytes is sufficiently great that their enzymes cause liquefaction of the affected tissues, focally or diffusely; the purulent exudate is frequently termed pus, and consists of plasma and its constituents, end products of the enzymatic digestion of tissue, degenerated and necrotic cells and their debris, polymorphonuclear leukocytes and other white blood cells, the causal agent of the inflammation, etc.
Synonym: suppurative inflammation.
(05 Mar 2000)
serofibrinous inflammation Inflammation in which the exudate consists chiefly of serous fluid with an unusually large proportion of fibrin.
(05 Mar 2000)
serous inflammation An exudative inflammation in which the exudate is predominantly fluid (e.g., exuded from the blood vessels), with the protein, electrolytes, and other material contained therein; relatively few (if any) cells are observed.
(05 Mar 2000)
hyperplastic inflammation An inflammatory reaction in which the distinguishing feature is an actual increase in the number of tissue cells, especially the reticuloendothelial macrophages, in contrast to cells exuded from blood vessels; in addition, exudates of various types are likely to be observed in granulomas and other forms of proliferative inflammation, but the latter may occur without an exudate being formed (as in certain infections caused by virus).
Synonym: hyperplastic inflammation.
(05 Mar 2000)
necrotic inflammation Usually an acute inflammatory reaction in which the predominant histologic change is fairly rapid necrosis that occurs diffusely or extensively in relatively large foci throughout the affected tissue, frequently with only little or no evidence of cells in the exudate.
(05 Mar 2000)
subacute inflammation An inflammation that is intermediate in duration between that of an acute inflammation and that of a chronic inflammation, usually persisting longer than 3 or 4 weeks.
(05 Mar 2000)
suppurative inflammation An acute exudative inflammation in which the accumulation of polymorphonuclear leukocytes is sufficiently great that their enzymes cause liquefaction of the affected tissues, focally or diffusely; the purulent exudate is frequently termed pus, and consists of plasma and its constituents, end products of the enzymatic digestion of tissue, degenerated and necrotic cells and their debris, polymorphonuclear leukocytes and other white blood cells, the causal agent of the inflammation, etc.
Synonym: suppurative inflammation.
(05 Mar 2000)
degenerative inflammation A local reaction to injury, occasionally observed in the walls of blood vessels and in parenchymal cells of various organs in reacting to certain chemicals, viruses, and other intracellular agents; the response is characterised by degenerative changes in the cytoplasm and nucleus, frequently resulting in necrosis, but exudation (if any) is ordinarily observed only in the wall of the affected vessel, or in the interstices immediately adjacent to the affected vessel or parenchymal cells.
Synonym: degenerative inflammation.
(05 Mar 2000)
immune inflammation See: allergic reaction.
(05 Mar 2000)
inflammation <pathology> A localised protective response elicited by injury or destruction of tissues, which serves to destroy, dilute or wall off (sequester) both the injurious agent and the injured tissue.
It is characterised in the acute form by the classical signs of pain (dolor), heat (calor), redness (rubor), swelling (tumour) and loss of function (functio laesa).
Histologically, it involves a complex series of events, including dilatation of arterioles, capillaries and venules, with increased permeability and blood flow, exudation of fluids, including plasma proteins and leucocytic migration into the inflammatory focus.
Origin: L. Inflammatio, inflammare = to set on fire
(11 Jun 1998)
inflammation: gallium imaging <radiology> Pathophysiology: leakage of protein-bound Ga-67 into extracellular space secondary to increased capillary permeability, Ga-67 is preferentially bound to nonviable PMNs and macrophages, leukocyte incorporation (rich in lactoferrin), bacterial uptake (siderophores), inflammtory tissue stimulates lactoferrin production for chronic abdominal inflammation: 67% sensitivity; 64% specificity; 13% false negatives; 5% false positive, dose: 5 mCi; imaging: 24, 48, 72 hours, diffuse uptake in peritonitis, localised uptake in acute pyogenic abscess, phlegmon, acute cholecystitis, acute pancreatitis, acute gastritis, diverticulitis, inflammatory bowel disease, surgical wound, pyelonephritis, perinephric abscess see: gallium indications, gallium vs. Indium
(12 Dec 1998)
inflammation mediators The endogenous compounds that mediate inflammation (autacoids) and related exogenous compounds including the synthetic prostaglandins (prostaglandins, synthetic).
(12 Dec 1998)
interstitial inflammation Inflammation in which the inflammatory reaction occurs chiefly in the supportive fibrous connective tissue or stroma of an organ.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á